TeklaLife Sciences Investors (HQL)
$20.57
$-0.41
(-1.95%)
As on 03-Sep-2026 15:39EDT
Market cap
$650 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
3.3
P/B Ratio
1.2
Div. Yield
8.4 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
--
-
Book Value
$17.8
-
EPS
$3
-
Face value
--
-
Shares outstanding
30,408,047
10 Years Aggregate
CFO
$-52.57 Mln
EBITDA
$484.77 Mln
Net Profit
$249.93 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| 22.6 | 7.7 | 19.7 | 46.3 | 16.1 | -1.2 | 1.1 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| 27.9 | -2.5 | -5.3 | -26.1 | -2.6 | 13.3 | 15.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
|
20.6 | 649.8 | 86.4 | 85.6 | -- | 17.6 | 3.3 | 1.2 |
| 16.0 | 1,649.2 | 225.0 | 222.0 | -- | 13.4 | 7.5 | 1.0 | |
| 30.7 | 2,089.1 | 266.0 | 314.4 | -- | 20.3 | 6.6 | 1.2 | |
| 12.3 | 3,291.2 | 948.0 | -375.0 | 6.8 | -6.7 | -- | 0.7 | |
| 67.3 | 1,599.1 | 24.4 | 376.7 | 10.6 | 20.5 | 4.2 | 0.9 | |
| 14.9 | 2,474.3 | 185.4 | 490.6 | -13.8 | 19.7 | 5.1 | 0.9 | |
| 15.4 | 1,183.0 | 325.8 | 321.3 | -- | 25.6 | 3.4 | 0.9 | |
| 18.6 | 1,757.2 | 101.9 | 174.1 | -- | 8 | 11.9 | 0.8 | |
| 22.6 | 1,333.7 | 99.8 | 98.6 | 527.8 | 9.2 | 5.3 | 1.2 | |
| 35.7 | 1,891.9 | 204.6 | 254.3 | -- | 13.1 | 7.2 | 1.0 |
Shareholding Pattern
View DetailsAbout TeklaLife Sciences Investors (HQL)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector,... including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Read more
-
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
-
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for TeklaLife Sciences Investors (HQL)
What is the current share price of TeklaLife Sciences Investors (HQL) Today?
The share price of TeklaLife Sciences Investors (HQL) is $20.57 (NYSE) as of 03-Sep-2026 15:39 EDT. TeklaLife Sciences Investors (HQL) has given a return of 16.14% in the last 3 years.
What is the current PB & PE ratio of TeklaLife Sciences Investors (HQL)?
The P/E ratio of TeklaLife Sciences Investors (HQL) is 3.33 times as on 21-Aug-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
5.23 |
0.87 |
2024 |
5.09 |
0.94 |
2023 |
14.95 |
0.83 |
2022 |
-3.35 |
0.88 |
2021 |
7.95 |
0.98 |
What is the 52 Week High and Low of TeklaLife Sciences Investors (HQL)?
The 52-week high and low of TeklaLife Sciences Investors (HQL) are Rs 22.67 and Rs 13.88 as of 04-Sep-2026.
What is the market cap of TeklaLife Sciences Investors (HQL)?
TeklaLife Sciences Investors (HQL) has a market capitalisation of $ 650 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in TeklaLife Sciences Investors (HQL)?
Before investing in TeklaLife Sciences Investors (HQL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.